Regeneron Pharmaceuticals (REGN) Pricing Misrepresentation Case
$REGN investors filed a lawsuit against Regeneron Pharmaceuticals for misrepresenting its pricing practices and financial performance related to its flagship drug.
On April 10, 2024, the DOJ accused Regeneron of failing to include certain discounts in Eylea’s pricing calculations, inflating Medicare reimbursements. Following this news, $REGN dropped by 3.36%.
$REGN investors can join this case to be notified about potential recovery.
Case Details:
Between November 2, 2023, and October 30, 2024, Regeneron assured investors that its finances were strong, supported by stable pricing and growing demand for its popular eye treatment, Eylea, and its higher-dose version, Eylea HD.
On April 10, 2024, the DOJ accused Regeneron of inflating Medicare reimbursements by failing to include certain discounts, such as credit card fee reimbursements, in Eylea’s pricing calculations.
On October 31, 2024, Regeneron reported disappointing sales for Eylea HD, blaming reduced pricing power and growing competition. These revelations raised doubts about Regeneron’s transparency and compliance.
Following this, $REGN dropped by 3.36%.
Based on these events, $REGN investors filed a lawsuit against Regeneron Pharmaceuticals, accusing the company of the following:
It misled investors about its pricing practices and compliance with Medicare regulations.
It overstated financial stability tied to its flagship product, Eylea.
Investors believe Regeneron concealed critical pricing risks and overstated Eylea’s performance.